JP2022535986A5 - - Google Patents

Info

Publication number
JP2022535986A5
JP2022535986A5 JP2021573749A JP2021573749A JP2022535986A5 JP 2022535986 A5 JP2022535986 A5 JP 2022535986A5 JP 2021573749 A JP2021573749 A JP 2021573749A JP 2021573749 A JP2021573749 A JP 2021573749A JP 2022535986 A5 JP2022535986 A5 JP 2022535986A5
Authority
JP
Japan
Prior art keywords
compound
general formula
alkyl
halo
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535986A (ja
Filing date
Publication date
Priority claimed from GBGB1908453.2A external-priority patent/GB201908453D0/en
Application filed filed Critical
Publication of JP2022535986A publication Critical patent/JP2022535986A/ja
Publication of JP2022535986A5 publication Critical patent/JP2022535986A5/ja
Pending legal-status Critical Current

Links

JP2021573749A 2019-06-12 2020-06-12 呼吸器の疾患を処置するためのtmem16aのモジュレータ Pending JP2022535986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1908453.2 2019-06-12
GBGB1908453.2A GB201908453D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease
PCT/GB2020/051414 WO2020249956A1 (en) 2019-06-12 2020-06-12 Modulators of tmem16a for treating respiratory disease

Publications (2)

Publication Number Publication Date
JP2022535986A JP2022535986A (ja) 2022-08-10
JP2022535986A5 true JP2022535986A5 (enExample) 2023-06-13

Family

ID=67386340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573749A Pending JP2022535986A (ja) 2019-06-12 2020-06-12 呼吸器の疾患を処置するためのtmem16aのモジュレータ

Country Status (6)

Country Link
US (1) US12415793B2 (enExample)
EP (1) EP3983069A1 (enExample)
JP (1) JP2022535986A (enExample)
CN (1) CN114269433B (enExample)
GB (1) GB201908453D0 (enExample)
WO (1) WO2020249956A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
JP2023531283A (ja) * 2020-06-30 2023-07-21 バイエル アクチェンゲゼルシャフト P2x4受容体拮抗作用を有する置換n-フェニルアセトアミド

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
GB9515975D0 (en) * 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
ES2210846T3 (es) * 1997-11-20 2004-07-01 Cerus Corporation Nuevos psoralenos para inactivar agentes patogenos.
EP1368323B1 (en) * 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DE10138578A1 (de) * 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
DE10160357A1 (de) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
DE10251019A1 (de) * 2002-11-02 2004-05-19 Aventis Pharma Deutschland Gmbh Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors
DE10300017A1 (de) 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Selektive MMP 13 Inhibitoren
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
US20110269834A1 (en) * 2008-08-21 2011-11-03 The Board Of Trustees Of The University Of Illinois Compounds and methods for treating respiratory diseases
FR2958849A1 (fr) * 2010-04-14 2011-10-21 Boiron Medicament homeopathique a activite anti-cancereuse
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
PE20150224A1 (es) * 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
US9505743B2 (en) * 2012-10-15 2016-11-29 Aquilus Pharmaceuticals, Inc. Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
EP3003275B1 (en) * 2013-06-03 2020-11-18 Bar-Ilan University Liposomes for modulating wiskott-aldrich syndrome protein
EP3020710A4 (en) * 2013-07-11 2016-12-14 Consejo Superior De Investig Científicas (Csic) OXAZOLIDINONE DERIVATIVES AS PPAR LIGANDS
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
US10112955B2 (en) * 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
WO2018200833A1 (en) * 2017-04-28 2018-11-01 Celgene International Ii Sarl Novel glp-1 receptor modulators
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
WO2019079609A1 (en) * 2017-10-20 2019-04-25 The Regents Of The University Of California SEH / PDE4 DOUBLE INHIBITORS AVAILABLE ORAL
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Similar Documents

Publication Publication Date Title
RU2763936C1 (ru) Производные 1,3,4-оксадиазола, как ингибитор гистондезацетилазы 6 и содержащая их фармацевтическая композиция
JP5578083B2 (ja) 2h−クロメン化合物及びその誘導体
JPS63258416A (ja) カルバゾリル−(4)−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び/又はβ−受容体閉塞作用を有する薬剤
RU2203897C2 (ru) Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство
KR101666729B1 (ko) Mgat2 억제제로서의 아릴 디히드로피리디논 및 피페리디논
US20040019113A1 (en) Phosphate transport inhibitors
EP1308438B9 (en) 3-substituted urea derivatives and medicinal use thereof
EA005369B1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
HUE026249T2 (en) Acrylamide derivatives may be used as inhibitors of mitochondrial permeability transition
JP2021512143A5 (enExample)
JP2007509852A5 (enExample)
JP2001509166A (ja) 糖尿病および肥満の治療のためのβ▲下3▼作動薬としてのチアゾールベンゼンスルホンアミド
WO2001025190A1 (en) Novel diarylamide derivatives and use thereof as medicines
JP2010513253A (ja) 炎症の治療に有用なベンゾオキサゾール類
RU2007107189A (ru) Производные арилпиридина
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
KR20070057965A (ko) 염증 및 면역 관련 용도를 위한 화합물
JP2756975B2 (ja) ピリジニウム誘導体
KR20120092655A (ko) Cns 장애 치료용 옥사졸린 유도체
JP2020533352A5 (enExample)
JP2022535986A5 (enExample)
JP2006528617A (ja) 5−ht2b受容体アンタゴニスト
JPWO2005026127A1 (ja) プラスミノゲンアクチベータインヒビター−1阻害剤
JP2008516902A5 (enExample)
JP2002503247A (ja) Pge2アゴニストおよびアンタゴニストとして有用なオキサゾール化合物